Hologic
JP Morgan Healthcare Conference, Day 2: CareDx, Thermo Fisher, BillionToOne, Adaptive Biotech, More
Highlights from the second day included BillionToOne's 2024 revenue spike and CareDx's plan to expand indications for its transplant tests.
Preliminary Earnings Roundup: Natera, Guardant Health, Exact Sciences, CareDx, GeneDx, More
Several molecular diagnostics firms reported fourth quarter and full-year 2024 revenues and other business updates ahead of the annual JP Morgan Healthcare Conference this week.
In Brief This Week: Adaptive Biotechnologies, Qiagen, OraSure Technologies, Hologic, More
News items for the week of Jan. 6, 2025.
Hologic Signs Deal With CDC for H5N1 Reagent Development
The US Centers for Disease Control and Prevention will support proof-of-concept development of primers and probes by Hologic for a laboratory-developed test.
Wolfe Research Begins Coverage of Hologic at Peer Perform, Tempus and Twist Bioscience at Outperform
Analyst Doug Schenkel said that Tempus has a broad and growing menu and Twist Bio has developed a novel DNA synthesis platform. He set $60 price targets for those companies.